BerandaAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
$12,08
Setelah Jam Perdagangan Normal:(0,99%)-0,12
$11,96
Tutup: 31 Des, 18.00.06 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$12,00
Rentang hari
$11,78 - $12,19
Rentang tahun
$2,61 - $16,96
Kapitalisasi pasar
1,33Â M USD
Volume Rata-Rata
1,44Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 16,17Â jt | -9,29% |
Penghasilan bersih | -34,39Â jt | 52,70% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,37 | 65,42% |
EBITDA | -35,91Â jt | 8,49% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 343,99Â jt | 46,76% |
Total aset | 362,74Â jt | 44,68% |
Total liabilitas | 30,74Â jt | -43,60% |
Total ekuitas | 332,00 jt | — |
Saham yang beredar | 109,82 jt | — |
Harga terhadap nilai buku | 3,97 | — |
Tingkat pengembalian aset | -32,32% | — |
Tingkat pengembalian modal | -35,20% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -34,39Â jt | 52,70% |
Kas dari operasi | -30,37Â jt | 26,95% |
Kas dari investasi | 5,24Â jt | -86,51% |
Kas dari pembiayaan | 191,61Â jt | 239.407,50% |
Perubahan kas bersih | 166,62Â jt | 6.934,50% |
Arus kas bebas | -14,62Â jt | 76,99% |
Tentang
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Didirikan
2013
Situs
Karyawan
123
